Equities

Bioxyne Ltd

Bioxyne Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.007
  • Today's Change0.001 / 16.67%
  • Shares traded165.80k
  • 1 Year change-72.00%
  • Beta1.4357
Data delayed at least 20 minutes, as of May 02 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioxyne Limited is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries Japan, Australia, the United Kingdom, and Czechia. The Company direct sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.

  • Revenue in AUD (TTM)8.65m
  • Net income in AUD-14.17m
  • Incorporated1998
  • Employees16.00
  • Location
    Bioxyne LtdSuite 506, Level 5, 50 Clarence StreetSYDNEY 2000AustraliaAUS
  • Phone+61 29078-8180
  • Fax+61 29078-7661
  • Websitehttps://bioxyne.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zelira Therapeutics Ltd1.62m-36.43m7.89m8.00------4.87-3.23-3.230.148-0.20630.08480.1853.55---193.14-27.71-243.04-28.8182.28---2,278.17-508.480.1488-22.80-----80.95-0.363553.35------
Anatara Lifesciences Ltd0.00-1.75m8.23m----6.49-----0.014-0.0140.000.00760.00-------103.15-59.64-115.72-66.52-------1,927.05----0.00------20.10---40.49--
TrivarX Ltd20.81k-3.74m8.80m4.00--1.05--422.90-0.0182-0.01820.000090.02490.0023-------42.02-41.56-47.15-50.51100.0092.74-17,949.78-334.16---147.210.0072---4.69-18.0675.85------
Avecho Biotechnology Ltd473.55k-3.44m11.09m29.00--1.74--23.42-0.0016-0.00160.00020.0020.08882.070.5132---64.45-47.08-75.73-55.25-9.2578.67-725.70-156.438.19--0.0267---58.07-19.42-46.71------
Oncosil Medical Ltd355.30k-11.71m11.28m2.00--2.56--31.74-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Firebrick Pharma Ltd0.00-4.57m11.30m----7.06-----0.0266-0.02660.000.00890.00-------120.70---136.04----------4.37--0.00---79.85---79.18------
Althea Group Holdings Ltd28.70m-20.99m11.75m----0.7667--0.4096-0.059-0.0590.07960.03780.61812.475.53---45.22-31.09-66.73-36.3254.6450.76-73.15-101.390.4899-46.550.2756--22.43335.18-13.21------
Bioxyne Ltd8.65m-14.17m12.28m16.00--3.94--1.42-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Vectus Biosystems Ltd86.39k-2.49m13.30m----5.61--153.98-0.0467-0.04670.00160.04450.0191-------54.95-96.22-68.14-691.17-----2,880.80-27,693.78---439.760.00--69,287.5097.8713.64------
Tissue Repair Ltd457.52k-3.28m13.67m----0.8601--29.88-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
BTC Health Ltd16.03k-8.26m13.94m1.00--2.578.44869.45-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Adalta Ltd3.56m-5.04m14.91m----6.08--4.19-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Medlab Clinical Ltd943.67k-6.78m15.07m14.00------15.97-2.97-2.970.41330.56040.13012.2510.35---88.67-55.07-127.20-69.7590.4552.86-681.73-335.431.67-217.550.00---28.90-29.8318.55---30.00--
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Nyrada Inc3.08m-4.98m16.51m----3.14--5.36-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Amplia Therapeutics Ltd1.87m-4.46m16.84m1.00--0.8389--9.01-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Data as of May 02 2024. Currency figures normalised to Bioxyne Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.